

Tel. : (91 832) 2257253 / 6714444

Fax : (91 832) 2257044

E-mail: gkbophthalmics@gkb.net

Website: www.gkb.net

GKB /STK-EXCH August 14, 2023

Department of Corporate Services BSE Limited Phiroze Jeejubhoy Towers Dalal Street Mumbai - 400 001

Ref: Scrip Code No.: 533212

Dear Sir,

Subject: Extract of Statement of audited Standalone and Consolidated Financial Results for the year ended June 30, 2023.

Please find attached copies of newspaper cuttings of the extract of Statement of audited Standalone and Consolidated Financial Results for the year ended June 30, 2023, published in The Financial Express (Mumbai Edition) and on Pudhari (Marathi) dated August 13, 2023.

Please acknowledge receipt.

Thanking you,

Yours faithfully,

For GKB Ophthalmics Ltd.,

Gurudas Sawant

Chief Financial Officer



FE SUNDAY

FINE - LINE CIRCUITS LIMITED

REGD.OFFICE: 145 SDF - V. SEEPZ, ANDHERI (EAST), MUMBAI - 400 096. CIN NO: L72900MH1989PLC13521 Email: fineline@fineline.co.in Phone No: 022 2829 0244/245, Fax No: 022 2829 2554,

Website: www.finelineindia.com

EXTRAC	T OF UNAUDITED FINANCIAL R 30TH JU	ESULTS FOR THE QUARTE INE, 2023	ER ENDED ON
		(Rs. i	n Lakhs except EPS)
Sr.	Particulars	Quarter ended	Year Ended

Sr.	Particulars		Quarter ended					
No.		30.06.2023	31.03.2023	30.06.2022	31.03.2023			
				(Audited)				
1)	Total Income from operations (Net)	520.83	733.66	670.35	2755.99			
2)	Net Profit/(Loss) from Ordinary Activities before Tax	(10.77)	(4.05)	5.11	6.62			
3)	Net Profit/(Loss) from Ordinary Activities after Tax	(10.97)	(0.76)	3.98	7.18			
4)	Total Comprehensive Income after Tax	(10.97)	11.00	3.98	18.94			
5)	Paid up equity share capital- (Face value of Rs.10/- each)	482.65	482.65	482.65	482.65			
6)	Reserves (Excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				368.91			
7)	Earning Per Share (EPS) (before extraordinary items)							
-050	(of Rs. 10/- each -Not annualised)							
SWIT.	(a) Basic & Diluted	(0.23)	(0.02)	0.08	0.15			
8)	Earning Per Share (EPS)(after extraordinary items)		33,000,000,000	X83C0	1612001			
	(of Rs. 10/- each -Not annualised)							
	(a) Basic & Diluted	(0.23)	(0.02)	0.08	0.15			

The above results have been prepared in accordance with Indian Accounting Standards (Ind AS), notified under section 133 of the Companies Act, 2013 read together with the Companies (Indian Accounting Standard) Rules, 2015, as amended.

The above is an extract of the Detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and other Discloure Requirements) Regulations, 2015 and the full format of the Quarterly Results are available on the Stock Exchange website bseindia.com and on the website of the Company at www.finelineindia.com

By Order of the Board

Place: Mumbai Date: 12th August, 2023

ABHAY B. DOSHI DIN: 00040644 **Managing Director**

INLAND

INLAND PRINTERS LTD.

Reg. Off.: 800, Sangita Ellipse, Sahakar Road, Vile Parle (East), Mumbai - 400057 Tel.: (022)-40482500 | Email: inlandprintersltd@gmail.com CIN: L99999MH1978PLC020739 | Website: www.inlandprinters.in

EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED JUNE 30, 2023

Particulars	Quarter ended 30.06.2023 (Unaudited)	Quarter ended 31.03.2023 (Audited)	Quarter ended 30.06.2022 (Unaudited)	Year ended 31.03.2023 (Audited)
Total Income from operation /Other income	- (5.07)	(11.04)	- /5.00\	(00.00)
Net Profit (Loss) from Ordinary Activities after Tax	(5.07)	(11.24)	(5.28)	(22.02)
Net Profit (Loss) for the period after Tax	(5.07)	(44.04)	(5.00)	(00.00)
(after Extraordinary items)	(5.07)	(11.24)	` ′	` ′
Paid-up Equity Share Capital	502.96	502.96	502.96	
Reserves (Excluding Revaluation Reserves)	-		-	(261.91)
Earnings Per Share (EPS)				
a) Basic and diluted EPS (before Extraordinary items)	(0.10)	(0.23)	(0.11)	(0.45)
b) Basic and diluted EPS (after Extraordinary items)	(0.10)	(0.23)	(0.11)	(0.45)
Notes:	10V	KI	2	0.

1) The above results have been published in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on 12th August, 2023. The financial results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The results have been audited by the Statutory Auditors of the Company. 2) Paid-up Equity Share Capital includes Rs. 8.58.500/- being the amount originally paid-up on forfeited shares.

3) Figures of the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.

4) The Board of Directors of Inland Printers Limited (the Transferee Company) in their meeting held on 9th March, 2023, had approved the scheme of Amalgamation under section 230 to 232 of the Companies Act, 2013 with Parthiv Corporate Advisory Private Limited (the Transferor Company). The said scheme is subject to the approval of the BSE and National Company Law Tribunal, Mumbai and other requisite approvals. Pending receipt of necessary approvals, no effect of the scheme has been given in the financials results for the quarter ended 30th June, 2023. The appointed date is fixed as 1st January, 2023.) The above is an extract of the detailed format of quarterly financial results for the quarter ended 30th June, 2023 filed with the Stock

Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the stock exchange website - www.bseindia.com and on Company's Website - www.inlandprinters.in

> By order of the Board For Inland Printers Limited **Kishor Sorap**

> > **Wholetime Director**

DIN.: 08194840

Place : Mumbai Date : 12th August, 2023

> **Hedge Finance Ltd** Reg. Off.: HEDGE HOUSE MAMANGALAM PALARIVATTOM P.O. KOCHI, Kerala – 682025, CIN: U65923KL2011PLC027672

Unaudited Financial Statement for the Quarter ended 30th JUNE 2023 (Standalone)

	[Regulation 52 (8) , read with Regulation 52 (4) , o	of the SEBI (LODR)	Regulations, 2015	Rs. in lakhs
		Quarter	Ended	Year Ended
SI.No	Particulars	June 30,2023 (Unaudited)	June 30 ,2022 (Unaudited)	March 31,2023 (Audited)
\vdash	Total Income from Operations	1061.30	844.01	3734.26
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/ or Extraordinary items)	169.89	39.95	327.33
3	Net Profit/ (Loss) for the period before tax (after Exceptional and/ or Extraordinary items)	169.89	39.95	327.33
4	Net Profit/ (Loss) for the period after tax (after Exceptional and/ or Extraordinary items)	132.63	30.29	238.87
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	132.63	30.29	233.89
6	Paid up Equity Share Capital	3401.65	2886.65	3401.65
7	Reserves (excluding Revaluation	885.48	549.25	752.85
8	Securities Premium Account		0	-
9	Net worth	4287.13	3435.90	4154.50
10	Paid up Debt Capital/ Outstanding Debt	5	5	-
11	Outstanding Redeemable Preference Shares *	j	2	-
12	Debt Equity Ratio *	4.77	5.17	4.64
13	Earnings Per Share (of Rs.10/- each)(for continuing and discontinued operations) -1. Basic: 2. Diluted:	0.39 0.39	0.12 0.12	0.79 0.79
14	Capital Redemption Reserve *	-	- 1	-
15	Debenture Redemption Reserve *	-	-	-
16	Debt Service Coverage Ratio *	NA	NA	NA
17	Interest Service Coverage Ratio *	NA	NA 1	NA

Note: a) The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with the Bombay Stock Exchange (BSE) under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the websites of the Bombay Stock Exchange (www.bseindia.com) and the Company (www.hedgefinance.com) b) For the items referred in sub-clauses (a), (b), (d) and (e) of the Regulation 52 (4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchange(s) (specify names of Stock Exchanges) and can be accessed on the URL (www.bseindia.com).

For and on behalf of the Board of Directors of Hedge Finance Ltd

Place: Kochi Date: 11.08.2023 Alex Kalluvila Babu Managing Director DIN: 01254207

Thomas Scott (India) Limited CIN: L18109MH2010PLC209302

Regd. Office: 50, Kewal Industrial Estate, S.B. Marg, Lower Parel (W), Mumbai- 400013 Tel.No.: (022) 4043 6363: Corp. Office: 405/406, Kewal Industrial Estate, 4th Floor, S.B. Marg, Lower Parel (W), Mumbai- 400013.

website: www.thomasscott.org Email Id: investor.tsil@banggroup.com Tel No.: (022) 6660 7965; Fax: (022) 6660 7970 **Extract of Unaudited Financial Results for the**

Quarter Ended 30th June 2023 (Rs. in Lakh except share per data Quarter Ended Year Ended

		rear Ended		
Doution love	30.06.2023	31.03.2023	30.06.2022	31.03.2023
Particulars	Unaudited	Unaudited	Unaudited	Audited
Total income from Operations	1,910.65	2,392.61	1,288.51	6,281.58
Net Profit / (Loss) before Tax				
(Before Exceptional and Extraordinary Items)	115.33	261.58	74.06	297.91
Net Profit / (Loss) before Tax				
(After Exceptional and Extraordinary Items)	115.33	261.58	74.06	297.91
Net Profit / (Loss) after Tax				
(After Exceptional and Extraordinary Items)	115.02	268.22	70.79	287.94
Other Comprehensive Income	-	1.03	-	-
Total Comprehensive Income (Comprising Profit/(Loss)				
after Tax and other comprehensive income after Tax)	115.02	269.25	70.79	287.94
Equity Share Capital (Face value of Rs. 10/- per share)	785.27	635.67	551.44	635.67
Reserves (Excluding Revalution Reserves as per				
Balance Sheet of previous Year)	-	-	-	-
Earnings Per Share (of 10 each) (in Rs.)				
(a) Basic	1.46	4.24	1.28	4.53
(b) Diluted	1.46	4.24	1.28	4.53

- Notes: 1) The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12th August 2023
- 2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised
- 3) Figures of the previous period have been regrouped/rearranged wherever necessary/practicable to confirm to the current presentation.
- 4) The Company is primarily engaged in single business segment of manufacturing and trading of textile products. In case of segment reporting of geographical segment for quarter ended June 2023, the export turnover of the Company is nil hence, no segment reporting has been done.

For Thomas Scott (India) Limited

Brijgopal Bang Managing Director

GKB OPHTHALMICS LIMITED

CIN: L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526

Tel No. (0832) 2257253 / 6714444 Fax No. (0832) 2257044 E-mail: gkbophthalmics@gkb.net Website: www.gkb.net

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2023

	Particulars		Star	ndalone		Consolidated				
SI.		â	Quarter en	ded	Year ended	Q	uarter ende	ed	Year ended	
No.	r articulars	30.06.23	31.03.23	30.06.22	31.03.23	30.06.23	31.03.23	30.06.22	31.03.23	
		Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	
1	Total Income from Operations	970.97	646.72	763.30	2,772.93	2,225.82	1,996.25	1,783.53	7,547.45	
2	Net Profit / (Loss) for the period (before Exceptional items and Tax)	7.58	(220.01)	5.22	(303.79)	55.47	(221.86)	215.34	10.62	
3	Net Profit / (Loss) for the period (after Exceptional items and before Tax)	7.58	(220.01)	5.22	(303.79)	55.47	(221.86)	215.34	10.62	
4	Net Profit / (Loss) for the period (after Exceptional items and Tax)	7.53	(211.50)	7.10	(288.12)	54.42	(207.93)	220.90	11.63	
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	7.37	(207.86)	5.69	(288.73)	54.26	(204.29)	219.49	11.02	
6	Equity Share Capital	504.06	504.06	504.06	504.06	504.06	504.06	504.06	504.06	
7	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)									
	(a) Basic (Rs.)	0.15	(4.20)	0.14	(5.72)	1.04	(3.80)	3.84	(0.33)	
	(b) Diluted (Rs.)	0.15	(4.20)	0.14	(5.72)	1.04	(3.80)	3.84	(0.33)	

Sr.

- 1. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 11, 2023.
- 2. The Group operates in one primary segment only, i.e. Ophthalmics Lenses and therefore Ind AS 108 Operating Segment is not applicable.
- 3. Board of Directors of the Company in its meeting held on August 12, 2022, had changed the accounting policy from April 1, 2022, by treating glass moulds as part of the inventory which were earlier treated as Property. Plant and Equipment ("PPE") and depreciated over its estimated useful life. Due to the change, "Depreciation and amortisation expense" for the quarter ended June 30, 2022 was lower by Rs. 31.48 lakhs and "Cost of materials consumed' was higher by Rs. 9.42 lakhs.
- However, Board of Directors of the Company had reviewed the change in the aforementioned accounting policy as at the year ended March 31, 2023 and concluded that the glass moulds were to be reinstated as PPE in line with the policy followed in the year ended March 31, 2022. The impact due to this change was reflected in the 'Depreciation and amortisation expense' for the guarter ended March 31, 2023 which had increased by Rs. 96.10 lakhs and 'Cost of materials consumed' had decreased by Rs. 24.85 lakhs. The above change had no impact on the amounts reported for the year ended March 31, 2023.
- 4. The figures for the guarter ended March 31, 2023 are balancing figures between the audited figures in respect of the full previous financial year and the published year-to-date figures up to the third guarter of the previous financial year which were subjected to limited review.
- Figures of the previous periods have been regrouped, wherever necessary.
- The above is an extract of the detailed format of guarterly / annual financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations, 2015. The full format of the guarterly / annual financial results are available on the Stock Exchange website (www.bseindia.com) and on Company's website (www.gkb.net).

Place: Mapusa - Goa

Date: 11th August, 2023

glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026; Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099. Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986 Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com CIN: L24299MH1977PLC019982

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2023

Quarter Quarter

Standalone

Quarter

(All amounts in million of Indian Rupees, unless otherwise stated) Consolidated

Quarter Quarter Quarter

For GKB Ophthalmics Limited K.G. Gupta

Managing Director

DIN: 00051863

No.	Particulars	ended 30/06/2023 (Unaudited)	ended 31/03/2023 (Audited)	ended 30/06/2022 (Unaudited)	ended 31/03/2023 (Audited)	ended 30/06/2023 (Unaudited)	ended 31/03/2023 (Audited)	ended 30/06/2022 (Unaudited)	ended 31/03/2023 (Audited)
1	Revenue from operations							7	
	(a) Net sales	20,980.62	18,749.65	18,722,38	80,196.66	33,361.47	33,006.13	27,200.97	127,254.33
	(b) Other operating income	463.22	640.83	396.92	2,009.96	654.56	731.02	571.92	2,646.77
	Total revenue from operations	21,443.84	19,390.48	19,119.30	82,206.62	34,016.03	33,737.15	27,772.89	129,901.10
H	Other income	493.61	2,329.65	3,465.18	9,859.39	208.72	(402.13)	1,831.55	3,167.86
Ш	Total income (I + II)	21,937.45	21,720.13	22,584.48	92,066.01	34,224.75	33,335.02	29,604.44	133,068.96
V	Expenses	100	86			7.5	91		
	(a) Cost of materials consumed	7,967.56	7,770.88	7,168.42	30,358.76	9,321.25	8,767.95	8,708.04	35,937.90
	(b) Purchases of stock-in-trade	821.71	860.54	940.54	3,911.92	4,069.30	2,303.92	2,518.47	12,682.58
	(c) Changes in inventories of finished goods,					99	191	00	
	work-in-progress and stock-in-trade	(230.84)	(64.33)	(300.82)	(313.65)	(1,110.56)	849.24	(1,106.05)	(3,250.94)
	(d) Employee benefits expense	3,344.66	3,061.20	3,022.97	13,465.08	7,294.05	6,575.79	6,363.67	27,809.56
	(e) Finance costs	619.34	588.60	397.63	2,068.16	1,120.04	1,092.56	599.89	3,495.83
	(f) Depreciation, amortisation and impairment expense	487.52	467.29	450.33	1,841.48	1,546.52	1,465.33	1,467.55	6,112.68
	(g) Other expenses	4,690.79	5,585.48	3,949.95	20,056.84	8,129.85	9,190.59	6,972.75	33,938.30
	Total expenses (IV)	17,700.74	18,269.66	15,629.02	71,388.59	30,370.45	30,245.38	25,524.32	116,725.91
V	Profit/(loss) before exceptional items and tax (III - IV)	4,236.71	3,450.47	6,955.46	20,677.42	3,854.30	3,089.64	4,080.12	16,343.05
VI	Exceptional items (gain)/ loss (Refer note 5)	316.29	6,583.72	2022	4,958.68	520.23	7,997.32		7,658.54
IIV	Profit/(loss) before tax (V - VI)	3,920.42	(3,133.25)	6,955.46	15,718.74	3,334.07	(4,907.68)	4,080.12	8,684.51
/111	Tax expense :	597855555575	West Developed Mile	\$560,000 NSS	50%.000000	187.757.757.75	N. P. C. Carrier (1995)	1.0000000000000000000000000000000000000	W. 128 S. P. B. S.
000	Current tax	385.65	846.54	1,103.57	3,869.31	1,003.22	1,671.33	1,352.37	5,669.01
	Deferred tax	818.21	(2,605.10)	926.08	(238.26)	599.57	(2,547.64)	616.68	(758.50)
X.	Profit/(loss) for the period (VII - VIII)	2,716.56	(1,374.69)	4,925.81	12,087.69	1,731.28	(4,031.37)	2,111.07	3,774.00
100	Profit/(loss) for the period attributable to:	20000		Ulfaration)	155551440	MIRANE	1000000000	25/11/15/01	
	- Non-controlling interests	S .	-	2	- 3	231.94	251.66	185.77	801.55
	- Owners of the Company	2,716.56	(1,374.69)	4,925.81	12,087.69	1,499.34	(4,283.03)	1,925.30	2,972.45
X	Other comprehensive income	Salat Mass		WESSER	137405.0000	Massaw	1000000		
	A (i) Items that will not be reclassified to profit or loss	(7.50)	(41.64)	91.37	9.71	(6.49)	110.14	99.78	161.21
	(ii) Income tax relating to items that will not be	30.55.73	(0.155.7)	230000	33800	150001	1,130,130	6200000	
	reclassified to profit or loss	2.23	14.55	(11.06)	(3.39)	2.47	(7.20)	(11.16)	(22.22)
	B (i) Items that will be reclassified to profit or loss		-	10.0000	120221	(564.37)	444.17	1,915.98	1,849.80
	(ii) Income tax relating to items that will be reclassified					AT/03/02/3/60	-3.707.83	600000000000000000000000000000000000000	
	to profit or loss		- 2			6.80	34.68	(220.32)	(451.52)
XI	Total comprehensive income for the period/ year	2,711.29	(1,401,78)	5,006.12	12,094.01	1,169.69	(3,449.58)	3,895.35	5,311.27
XII	Total comprehensive income attributable to:	1772/1775	MARKET STREET	SERVICE	100000000	MARKE	100000000000000000000000000000000000000		
	- Non-controlling interests		2)		(%	231.98	252.29	185.89	800.83
	- Owners of the Company	2,711.29	(1,401.78)	5,006.12	12,094.01	937.71	(3,701.87)	3,709.46	4,510.44
KIII	Paid up Equity Share Capital, Equity Shares of ₹ 1/- each	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17
(IV	Other equity (other than revaluation reserve)	35555.11			178,492.46	204.00	3000.77	202317	94,457.06
XV	Earning per share (EPS)				110,106,10				V 11 TO 1.00
38	(not annualised except for the year ended 31 March)								
	Basic (in Rupees)	9.63	(4.87)	17.46	42.84	5.31	(15.18)	6.82	10.53
	Diluted (in Rupees)	9.63	(4.87)	17.46	42.84	5.31	(15.18)	6.82	10.53

- 1. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2. The above results were reviewed by the Audit Committee at its meeting held on 10th August, 2023 and approved by the Board of Directors at their meetings held on 11th August, 2023. The results for the quarter ended 30th June. 2023 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- 3. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- As at 30th June, 2023, pursuant to Employee Stock Options Scheme 2016, 78,717 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- 5. Exceptional item: 30 June 2023 :

Exceptional item of ₹ 520.23 in the consolidated result for the quarter comprises of remediation cost of manufacturing sites in India and Monroe (USA) . Exceptional item of ₹ 316.29 in the standalone result for the quarter comprises of remediation cost of manufacturing sites in India

The Company and its US subsidiary (Glenmark Pharmaceuticals Inc., USA) have, subject to final documentation and approval of the Court, after the end of the accounting year, arrived at a settlement with Three Plaintiff Groups collectively representing all of the claims against the Company and Merck in relation to multiple antitrust and consumer protection lawsuits, including a class action, consolidated in the Eastern District of Virginia, U.S. (the "Court") for a total amount of US\$ 87.5mn (US Dollar Eighty Seven Point Five million), payable over two financial years. The final settlements will be in accordance with the separate agreements entered into with each of the plaintiff groups and will be subject to the final approval by the Court. The settlements will make clear that the settlements are commercial settlements of civil liabilities and not on the basis of the Company having conceded or admitted any liability, offence, wrongdoing or illegality.

In view of the above and as a prudent measure, the Company has made a provision for the estimated settlement amount of ₹ 8,010.53 (equivalent of US\$ 87.5 million and related costs) and charged the same to profit and loss account for the year ended 31 March 2023. Due to the non-recurring nature of the provision, the Company has classified this provision as an exceptional item in the financial statements for the guarter and year ended 31 March 2023. The resultant deferred tax asset of Rs. 2,799,20 has also been recognised. On finalisation of settlement agreements and final approval of the Court, the crystallized liability will be accounted after adjusting the provisions in this respect in the year of final settlement and Court approval.

Exceptional item in the consolidated result for the quarter also includes a net gain of ₹ 13.21 arising from the divestment of select tail brands and sub-brands from the dermatology segment (India and Nepal business), net of trade expenses, trade receivables, inventory write-off, other reimbursable expenses and remediation cost of Monroe manufacturing site (USA) and India manufacturing sites. The exceptional item for the year ended 31 March 2023 additionally includes gain on sale of cardiac brand Razel (India and Nepal business), net of trade expenses, trade receivables, inventory write-off, other reimbursable expenses and remediation cost of Monroe manufacturing site (USA).

Exceptional item in the standalone result for the quarter includes a net gain of ₹ 1,426.81 arising from the divestment of select tail brands and sub-brands from the dermatology segment (India and Nepal business), net of trade expenses, trade receivables, inventory write-off and other reimbursable expenses and remediation cost of India manufacturing sites. The exceptional item for the year ended 31 March 2023 additionally includes gain on sale of cardiac brand Razel (India and Nepal business), net of trade expenses, trade receivables, inventory write-off, other reimbursable expenses.

- 6. The figures for the quarter ended 31st March 2023 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third guarter ended 31st December, 2022. The list of subsidiaries as of 30th June, 2023 is provided in Annexure A.
- Diluted EPS has been computed considering the effect of conversion of ESOPs.
- Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period. Glenmark Pharmaceuticals Limited

Annexure A

List of entities included in the consolidated financial results for the guarter ended 30 June 2023

1. Glenmark Pharmaceuticals Europe Ltd., U.K. 2. Glenmark Pharmaceuticals S.R.O. 3. Glenmark Pharmaceuticals SK, S.R.O. 4. Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 5. Glenmark Holding S.A. 6. Glenmark Pharmaceuticals SP z.o.o. 7. Glenmark Pharmaceuticals Inc. 8. Glenmark Therapeutics Inc. 9. Glenmark Farmaceutica Ltda 10. Glenmark Generics S.A 11. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 12. Glenmark Pharmaceuticals Peru SAC 13. Glenmark Pharmaceuticals Colombia SAS, Colombia 14. Glenmark Uruguay S.A. 15. Glenmark Pharmaceuticals Venezuela, C.A 16. Glenmark Dominicana SRL 17. Glenmark Pharmaceuticals Egypt S.A.E. 18. Glenmark Pharmaceuticals FZE 19. Glenmark Impex L.L.C 20. Glenmark Philippines Inc. 21. Glenmark Pharmaceuticals (Nigeria) Ltd 22. Glenmark Pharmaceuticals Malaysia Sdn Bhd 23. Glenmark Pharmaceuticals (Australia) Pty Ltd 24. Glenmark South Africa (pty) Ltd 25. Glenmark Pharmaceuticals South Africa (pty) Ltd 26. Glenmark Pharmaceuticals (Thailand) Co. Ltd 27. Glenmark Pharmaceuticals B.V. 28. Glenmark Pharmaceuticals Canada Inc. 30. Glenmark Pharmaceuticals Kenya Ltd 31. Viso Farmaceutica S.L., Spain 32. Glenmark Specialty SA 33. Glenmark Pharmaceuticals Distribution s.r.o. 34. Glenmark Pharmaceuticals Nordic AB 35. Glenmark Ukraine LLC 36. Glenmark Pharmaceuticals Ecuador S.A. 37. Glenmark Pharmaceuticals Singapore Pte. Ltd. 38. Ichnos Sciences Biotherapeutics SA 39. Ichnos Sciences Inc., USA 40. Glenmark Life Sciences Limited 41. Glenmark Healthcare Limited (with effect from 12th May 2023) 42. Glenmark Farmaceutica SpA (with effect from 1st March 2023) 43. Sintesy Pharma S.R.L (with effect from 10th February 2023)

> For and on behalf of the Board of Directors Glenn Saldanha

> > Chairman & Managing Director

Mumbai, 11 August 2023

Place: Mumbai Date: 12th August 2028 papr.in

accounting practices and policies to the extent applicable.

(DIN: 00112203)





जीकेबी ऑप्थालमिक्स लिमिटेड CIN: L26109GA1981PLC000469

नोंदणीकृत कार्यालय : १६-ए, थिवी औद्योगिक वसाहत, म्हापसा गोवा ४०३ ५२६

फोन क्र. (०८३२) २२५७२५३ / ६७१४४४४, फॅक्स क्र. (०८३२) २२५७०४४, ई मेल : gkbophthalmics@gkb.net वेबसाईट : www.gkb.net

३० जून २०२३ रोजी संपलेल्या तिमाहीसाठीच्या अलेखापरिक्षित आर्थिक परिणामांच्या स्टेटमेंटचा सारांश

रु. लाखात

			कन्सोलेटेड						
अ.	तपशील		तिमाही अखेर		वर्ष अखेर		तिमाही अखे	t	वर्ष अखेर
क्र.	તપશાલ	30/05/23	38/03/23	३०/०६/२२	39/03/23	30/08/23	39/03/23	30/05/22	39/03/23
		अलेखापरिक्षीत	लेखापरिक्षीत	अलेखापरिक्षीत	लेखापरिक्षीत	अलेखापरिक्षीत	लेखापरिक्षीत	अलेखापरिक्षीत	लेखापरिक्षीत
٧.	व्यवहारातून झालेली एकूण मिळकत	900.90	६४६.७२	७६३.३०	२,७७२.९३	२,२२५.८२	१,९९६.२५	१,७८३.५३	७,५४७.४५
₹.	कालावधीसाठी निव्वळ नफा/(नुकसान) (अपवादात्मक वस्तू आणि करपूर्व)	6.46	(२२०.०१)	4.22	(303.69)	44.80	(२२१.८६)	२१५.३४	१०.६२
3.	कालावधीसाठी निव्वळ नफा/(नुकसान) (अपवादात्मक वस्तूंनंतर आणि करपूर्व)	७.५८	(२२०.०१)	4.22	(90,505)	44.89	(२२१.८६)	२१५.३४	१०.६२
٧.	कालावधीसाठी निव्वळ नफा/(नुकसान) (अपवादात्मक वस्तूंनंतर आणि करोत्तर)	७.५३	(२११.५०)	9.80	(२८८.१२)	48.82	(२०७.९३)	220.90	११.६३
4.	कालावधीसाठी एकूण व्यापक मिळकत (कालावधीसाठीचा नफा/(तोटा)(करोत्तर)	110450		0.000	17525 1-030		- 350 - 11 P.O.C.	1 100000	3505 11.5
	आणि इतर व्यापक मिळकत (करोत्तर))	9.30	(३०७.८६)	५.६९	(१८८.७३)	५४.२६	(२०४.२९)	२१९.४९	११.०२
ξ.	समभाग भांडवल	५०४.०६	५०४.०६	५०४.०६	५०४.०६	५०४.०६	५०४.०६	५०४.०६	५०४.०६
19.	दर शेयर मिळकत(प्रत्येकी रु. १०/-)(चालू आणि बंद व्यवहारांसाठी)			13300000000			10-10-24		
	अ) बेसिक (रूपयांत)	0.84	(8.20)	0.88	(५.७२)	१.०४	(3.60)	3.८४	(0.33)
	ब) डायल्युटेड (रूपयांत)	0.84	(8.20)	0.88	(५.७२)	8.08	(3.60)	3.28	(0.33)

रीप

- १. वरील आर्थिक परिणामांचे लेखा परीक्षण समितीने पुनर्परिक्षण केले आहे आणि संचालक मंडळाने ऑगस्ट ११,२०२३ रोजी झालेल्या संबंधित बैठकांमध्ये त्याला मंजुरी दिली आहे.
- २. कंपनी केवळ एकाच प्रायमरी सेगमेंटमध्ये कार्यरत आहे, म्हणजे ऑप्थॅल्मिक्स लेन्सेसमध्ये आणि म्हणून भारतीय लेखा मानद ('इंड एएस') १०८ ऑपरेटींग सेगमेंट इथे लागृ होत नाही.
- ३. कंपनीच्या संचालक मंडळाने त्यांच्या ऑगस्ट १२, २०२२ रोजी झालेल्या बैठकीत एप्रिल १,२०२२ पासून ऑप्थॅल्मिक लेन्सेसच्या उत्पादनात वापरण्यात येणाऱ्या स्लास मोल्ड्सच्या हिशोबासाठीचे धोरण बदलले आहे. या बदलामुळे, जून ३०, २०२३ मध्ये संपलेल्या तिमाहीसाठीचा 'घसारा आणि कर्जमाफी खर्च 'रू. ३१.४८, लाखांनी कमी झाला आणि 'वापरलेल्या सामग्रीचे मूल्य 'रू. ९,४२ लाखांनी वाढले आहे. तथापि, कंपनीच्या संचालक मंडळाने वरील हिशोब धोरणातील बदलाचे पुनर्विलोकन मार्च ३१, २०२३ रोजी संपलेल्या वर्षात केले आणि निष्कर्ष काढला की मार्च ३१, २०२२ रोजी संपलेल्या वर्षात अवलंबलेल्या धोरणाप्रमाणेच ग्लास मोल्ड्स पीपीई पुनर्स्थापित
 - तथापि, कंपनीच्या संचालक मंडळाने वरील हिशोब धोरणातील बदलाचे पुनर्विलोकन मार्च ३१, २०२३ रोजी संपलेल्या वर्षात केले आणि निष्कर्ष काढला की मार्च ३१, २०२२ रोजी संपलेल्या वर्षात अवलंबलेल्या धोरणाप्रमाणेच ग्लास मोल्ड्स पीपीई पुनर्स्थापित केले गेले. याचा परिणाम मार्च ३१, २०२३ रोजी संपलेल्या तिमाहीसाठीच्या 'घसारा आणि कर्जमाफी खर्च' यात दिसून आला जो रू. ९६.१० लाखांनी वाढला 'वापरलेल्या सामग्रीचे मूल्य' रू. २४.८५ लाखांनी कमी झाले. वरील बदलाचा मार्च ३१, २०२३ रोजी संपलेल्या वर्षासाठी अहवाल केलेल्या रकमांवर काहीही परिणाम झालेला नाही.
- ४. मार्च ३१,२०२३ रोजी संपलेल्या तिमाहीतील आकडेवारी ही संपूर्ण मागील आर्थिक वर्ष आणि मागील आर्थिक वर्षाच्या तिसऱ्या तिमाहीपर्यंतचे आतापर्यंतचे वर्ष या दरम्यानची संतुलित आकडेवारी आहे जिचे मर्यादित परिक्षण होऊ शकते.
- मागील कालावधीतील आकडेवारी ही, जिथे आवश्यकता भारेल तिथे पुनर्वर्गीकृत केली आहे.
- ६. वरील तिमाही/वार्षिक आर्थिक परिणामांच्या तपशीलवार प्रारूपाचा सारांश असून हा स्टॉक एक्सेंजमध्ये सेबीच्या नियम ३३ (लिस्टींग अँड ऑब्लिगेशन्स डिसक्लोजर रिक्कायरमेंट्स) नियम,२०१५ नुसार दाखल करण्यात आला आहे. तिमाही/वार्षिक आर्थिक परिणामांचे संपूर्ण प्रारूप शेअर बाजाराची वेबसाईट वेबसाईट्सवर उपलब्ध आहे. www.bseindia.com आणि कंपनीची वेबसाईट www.gkb.net वर उपलब्ध आहे.

ठिकाण : म्हापसा-गोवा दिनांक : ११ ऑगस्ट, २०२३ जीकेबी ऑप्थॅल्पिक्स लिमिटेडसाठी के. जी. गुप्ता व्यवस्थापकीय संचालक डीआयएन: ०००५१८६३